UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A679-A679

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis

International journal of geriatric psychiatry, 2011-06, Vol.26 (6), p.564-572

2011

Link zum Volltext

Verfügbarkeit prüfen

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Cancer Research and Treatment, 2018, 50(2), , pp.398-404

2018

Link zum Volltext

Verfügbarkeit prüfen

MO50-3 Preliminary data from the phase I/II study of TP-3654, an oral PIM-1 kinase inhibitor, in patients with myelofibrosis

Annals of oncology, 2023-11, Vol.34, p.S1427-S1427

2023

Link zum Volltext

Verfügbarkeit prüfen

Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

Journal of Crohn's and colitis, 2017-08, Vol.11 (8), p.921-929

2017

Link zum Volltext

Verfügbarkeit prüfen

Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1

Inflammatory bowel diseases, 2019-03, Vol.25 (4), p.803-810

2019

Link zum Volltext

Verfügbarkeit prüfen

Poster: MPN-161: A Phase I Study of TP-3654, an Oral PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis (MF)

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S235-S235

2021

Link zum Volltext

Verfügbarkeit prüfen

MPN-161: A Phase I Study of TP-3654, an Oral PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis (MF)

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S355-S356

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract P223: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P223-P223

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

British journal of clinical pharmacology, 2016-09, Vol.82 (3), p.728-738

2016

Link zum Volltext

Verfügbarkeit prüfen

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis

British journal of haematology, 2016-09, Vol.174 (5), p.748-759

2016

Link zum Volltext

Verfügbarkeit prüfen

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

European journal of cancer (1990), 2019-01, Vol.106, p.89-98

2019

Link zum Volltext

Verfügbarkeit prüfen

High-performance prediction of functional residues in proteins with machine learning and computed input features

Biopolymers, 2011-06, Vol.95 (6), p.390-400

2011

Link zum Volltext

Verfügbarkeit prüfen

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

Targeted oncology, 2017-10, Vol.12 (5), p.643-654

2017

Link zum Volltext

Verfügbarkeit prüfen

P-140 Pharmacokinetic/Pharmacodynamic Relationship and Immunogenicity of Vedolizumab in Adults with Inflammatory Bowel Disease: Additional Results from GEMINI 1 and 2

Inflammatory bowel diseases, 2013-12, Vol.19, p.S80

2013

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

Journal of hematology and oncology, 2015-09, Vol.8 (1), p.103, Article 103

2015

Link zum Volltext

Verfügbarkeit prüfen

Evolution of Enzymatic Activities of Testis-Specific Short-Chain Dehydrogenase/Reductase in Drosophila

Journal of molecular evolution, 2010-10, Vol.71 (4), p.241-249

2010

Link zum Volltext

Verfügbarkeit prüfen

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Cancer research and treatment, 2018-04, p.398-404

2018

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

Journal of Crohn's and colitis, 2018-03, Vol.12 (4), p.510-510

2018

Link zum Volltext

Verfügbarkeit prüfen

An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017-09, Vol.17, p.S333-S334

2017

Link zum Volltext

Verfügbarkeit prüfen

Statistical criteria for the identification of protein active sites using theoretical microscopic titration curves

Proteins, structure, function, and bioinformatics, 2005-05, Vol.59 (2), p.183-195

2005

Link zum Volltext

Verfügbarkeit prüfen

Metabolic Assessment of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Pooled Analysis of 2 Studies

Journal of clinical psychopharmacology, 2009-08, Vol.29 (4), p.362-367

2009

Link zum Volltext

Verfügbarkeit prüfen

Future directions in protein function prediction

Molecular biology reports, 2002-12, Vol.29 (4), p.329-335

2002

Link zum Volltext

Verfügbarkeit prüfen

Treatment Effect Estimation in Adaptive Clinical Trials: A Review

Applied Statistics in Biomedicine and Clinical Trials Design, p.197-202

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 53

Suche als RSS-Feed

Aktive Filter

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(50)
Buchkapitel
(3)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer

Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

MO50-3 Preliminary data from the phase I/II study of TP-3654, an oral PIM-1 kinase inhibitor, in patients with myelofibrosis

Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1

Poster: MPN-161: A Phase I Study of TP-3654, an Oral PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis (MF)

MPN-161: A Phase I Study of TP-3654, an Oral PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis (MF)

Abstract P223: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

High-performance prediction of functional residues in proteins with machine learning and computed input features

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

P-140 Pharmacokinetic/Pharmacodynamic Relationship and Immunogenicity of Vedolizumab in Adults with Inflammatory Bowel Disease: Additional Results from GEMINI 1 and 2

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

Evolution of Enzymatic Activities of Testis-Specific Short-Chain Dehydrogenase/Reductase in Drosophila

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Statistical criteria for the identification of protein active sites using theoretical microscopic titration curves

Metabolic Assessment of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Pooled Analysis of 2 Studies

Future directions in protein function prediction

Treatment Effect Estimation in Adaptive Clinical Trials: A Review

Aktive Filter

Suchergebnisse filtern